All News

Giredestrant improved invasive disease–free survival vs endocrine therapy for patients with ER+, HER2– early breast cancer in the phase 3 lidERA trial.

GLP-1 receptor agonist use was tied to reduced HR+/HER2− breast cancer incidence and improved overall survival in nondiabetic women with elevated BMI.

Fred Saad, MD, FRCS, CQ, FCAHS, discussed the clinical benefits of introducing lutetium Lu 177-PSMA-617 earlier to delay progression to mCRPC.

First-line sacitizumab govitecan plus pembrolizumab prolonged PFS2 PD-L1+ metastatic triple-negative breast cancer.

Patients with breast cancer experienced improvement in vasomotor symptoms when treated with elinzanetant, irrespective of type of endocrine therapy.

Leveraging 6-month PSA and PSMA-PET metrics may guide therapy escalation or de-escalation in metastatic hormone-sensitive prostate cancer.

Switching to camizestrant plus CDK4/6i upon ESR1 mutation detection demonstrated a PFS of 7.6 months and achieved significant PFS2 benefit in SERENA-6.

The ivonescimab-based regimen appeared effective in both platinum-sensitive and platinum-resistant cohorts in a phase 2 study.

Giredestrant plus palbociclib improved PFS numerically but not significantly vs letrozole plus palbociclib in 1L ER+, HER2– mBC.

Findings from the I-SPY 2.2 trial may show an important step toward treatment de-escalation for certain patients with HER2-negative breast cancer.

Grade 3 or higher TRAEs occurred in 73.7% of patients with HCC who received camrelizumab plus rivoceranib and TACE vs 28.7% who received TACE alone.

Data from the VIKTORIA-1 trial support the PAM pathway as a molecular driver in HR-positive, HER2-negative breast cancer of any PIK3CA mutation status.

Data from the PANKU-Breast02 trial may support iza-bren as a new standard of care in this TNBC population.

More than 90% of patients achieved a composite complete response to azacitidine plus venetoclax and ivosidenib in a phase 1b/2 trial.

Modulation of angiogenic and immune-related pathways in ccRCC might provide rationale for checkpoint- or VEGFR-TKI–based combinations with HC-7366.

The nilotinib tablets may support patients who have difficulty swallowing while offering flexibility to take treatment with or without water.

Results from cohort C of the TRASTS study showed trabectedin/radiotherapy had positive response rates for patients with resectable retroperitoneal L-sarcomas.

Findings from the OptimUM-02 trial may support a new potential therapeutic standard for patients with HLA-A*02:01–negative metastatic uveal melanoma.

Atebimetinib plus modified gemcitabine/nab-paclitaxel demonstrated an ORR of 36% and median OS of 17.3 months in first-line metastatic pancreatic cancer.

The hypofractionated radiotherapy schedule was noninferior to the standard fractionation schedule regarding HRQOL for patients with cervical cancer.

Fedratinib may target various proliferative pathways in MDS/MPN that other current standards of care miss, according to Andrew Kuykendall, MD.

For patients with early breast cancer receiving chemotherapy, the use of a dexamethasone mouthwash did not significantly reduce the incidence of oral mucositis.

The FLAME trial showed osimertinib plus carboplatin/pemetrexed significantly improved PFS vs osimertinib monotherapy in ctDNA-persistent EGFR-mutant NSCLC.

The role of adjuvant immunotherapy remains unclear in this NSCLC population following data from the phase 3 ALCHEMIST trial.

Final analysis of KEYNOTE-522 confirms pembrolizumab plus chemotherapy improves event-free and overall survival in high-risk early-stage TNBC.

Cost-utility analysis of the CHALLENGE trial showed structured exercise following adjuvant chemotherapy for colon cancer is cost-saving and improves QALYs.

Patients with positive images may benefit from additional, non-androgen receptor-directed therapy, however prospective validation is required.

Findings from a study exploring how AI-driven NCCN guideline interpretation can optimize genetic testing and reduce clinician burden in prostate cancer.

Seven-year data from the CROWN study show improved PFS with lorlatinib over crizotinib among patients with ALK-positive non–small cell lung cancer.

A matching-adjusted indirect comparison highlighted linvoseltamab as a potentially effective treatment option for those with triple-class–exposed disease.